Related references
Note: Only part of the references are listed.2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes A randomized 26-week study on glycemic control and hypoglycemia
Baptist Gallwitz et al.
DIABETES CARE (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial
W. Yang et al.
DIABETES OBESITY & METABOLISM (2011)
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
A. Garber et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
Y. Seino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus
Masatoshi Kikuchi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
Exenatide Versus Glibenclamide in Patients with Diabetes
G. Derosa et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2010)
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
C. Filozof et al.
DIABETIC MEDICINE (2010)
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
T. Forst et al.
DIABETIC MEDICINE (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
B. Goke et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
Richard Bergenstal et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Advantages of insulin pump therapy
K. Akram et al.
DIABETIC MEDICINE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia
S. G. H. A. Swinnen et al.
DIABETOLOGIA (2009)
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naive Patients with Type 2 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2009)
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
A. R. Chacra et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2008)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration
S. R. Heller et al.
DIABETOLOGIA (2007)
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
R. Scott et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
G Schernthaner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) A 12-week, double-blind, randomized, controlled trial
S Madsbad et al.
DIABETES CARE (2004)
Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes - A population-based study of health service resource use
GP Leese et al.
DIABETES CARE (2003)